DANIEL ROSSI DE CAMPOS

Dr. DANIEL ROSSI DE CAMPOS


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in Catalysts
Verified
Journal Article
Open access
PDF file
Fabiano ContesiniFabiano Contesini
Fabiano Contesini
Marcelo Gomes DavançoMarcelo Gomes Davanço
Marcelo Gomes Davanço
GBGustavo Pagotto Borin
Gustavo Pagotto Borin
KVKatherina Garcia Vanegas
Katherina Garcia Vanegas
JCJoão Pedro Gonçalves Cirino
João Pedro Gonçalves Cirino
PCPatricia de Oliveira Carvalho
Patricia de Oliveira Carvalho
Lipases are one of the most used enzymes in the pharmaceutical industry due to their efficiency in organic syntheses, mainly in the production of enantiopure drugs. From an industrial viewpoint, the selection of an efficient expression system and host for recombinant lipase production is highly important. The most used hosts are Escherichia coli and Komagataella phaffii (previously known as Pichia pastoris) and less often reported Bacillus and Aspergillus strains. The use of efficient expression systems to overproduce homologous or heterologous lipases often require the use of strong promoters and the co-expression of chaperones. Protein engineering techniques, including rational design and directed evolution, are the most reported strategies for improving lipase characteristics. Additionally, lipases can be immobilized in different supports that enable improved properties and enzyme reuse. Here, we review approaches for strain and protein engineering, immobilization and the application of lipases in the pharmaceutical industry.

1 April 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Marcelo Gomes DavançoMarcelo Gomes Davanço
Marcelo Gomes Davanço
DCDANIEL ROSSI DE CAMPOS
DANIEL ROSSI DE CAMPOS
PCPatricia de Oliveira Carvalho
Patricia de Oliveira Carvalho

17 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marival BermejoMarival Bermejo
Marival Bermejo
JMJessica Meulman
Jessica Meulman
Marcelo Gomes DavançoMarcelo Gomes Davanço
Marcelo Gomes Davanço
PCPatricia de Oliveira Carvalho
Patricia de Oliveira Carvalho
Isabel Gonzalez-AlvarezIsabel Gonzalez-Alvarez
Isabel Gonzalez-Alvarez
DCDANIEL ROSSI DE CAMPOS
DANIEL ROSSI DE CAMPOS
The aim of the present study was to bring additional evidence regarding a biopredictive dissolution medium containing 1% sodium lauryl sulphate (SLS) to predict the in vivo behavior of carbamazepine (CBZ) products. Twelve healthy volunteers took one immediate release (IR) dose of either test and reference formulations in a bioequivalence study (BE). Dissolution profiles were carried-out using the medium. Level A in vitro–in vivo correlations (IVIVC) were established using both one-step and two-step approaches as well as exploring the time-scaling approach to account for the differences in dissolution rate in vitro versus in vivo. A detailed step by step calculation was provided to clearly illustrate all the procedures. The results show additional evidence that the medium containing 1% SLS can be classified as a universal biopredictive dissolution tool, and that both of the approaches used to develop the IVIVC (one and two-steps) provide good in vivo predictability. Therefore, this biopredictive medium could be a highly relevant tool in Latin-American countries to ensure and check the quality of their CBZ marketed products for which BE studies were not requested by their regulatory health authorities.